All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium–177 Octreotate
Therapeutic Area: Oncology Product Name: Lu-DOTATATE
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 12, 2021
Details:
POINT Biopharma has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium–177 Octreotate for the treatment of neuroendocrine cancer. Lu-DOTATATE as it is being used in 167 neuroendocrine tumor patients in a 180-patient trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Robust overall survival and sustained efficacy outcomes during long term exposure to Momelotinib in JAK inhibitor Naïve and previously JAK Inhibitor treated intermediate/high risk myelofibrosis patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $19.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 18, 2020
Details:
Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme, the 15-patient REM-001 confirmatory lead-in study and for working capital.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Mr. Kevin Norrett will support Sierra's MOMENTUM Phase 3 trial and delivering a high-quality outcome that may enable momelotinib's global registration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Darolutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bayer HealthCare
Deal Size: $31.3 million Upfront Cash: Undisclosed
Deal Type: Agreement May 20, 2020
Details:
The transaction follows the Sales of Nubeqa® (darolutamide), jointly developed by Orion Corporation and Bayer for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), started in the EU and Japan.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
